Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.
暂无分享,去创建一个
J. Neal | E. Felip | R. Gentzler | S. Werneke | J. Baranda | M. Simonelli | S. Ponce Aix | Shiven B. Patel | S. P. Aix | B. Fang | D. Curran | F. Lim | C. Squillante